Drug intelligence / Profile preview

aspirin + pravastatin

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

Aspirin + pravastatin is a fixed-dose combination drug containing two active ingredients with complementary cardiovascular protective effects. Pravastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting its synthesis in the liver, thereby reducing low-density lipoprotein (LDL) cholesterol and total cholesterol levels. This helps prevent atherosclerosis and related cardiovascular events. Aspirin (acetylsalicylic acid) acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), which reduces thromboxane A2 production and thus platelet aggregation, lowering the risk of blood clots that can cause heart attacks or strokes. The combination is primarily indicated for patients with coronary heart disease to treat high cholesterol and reduce the risk of myocardial infarction, stroke, or other serious cardiovascular complications[1][2][3][6][7]. Clinical studies have demonstrated additive benefits in secondary prevention of cardiovascular disease when both agents are used together compared to either alone[4][6][7].

Brand names
Pravigard Pac
Other names
aspirin and pravastatinpravastatin-acetylsalicylic acid combination
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on aspirin + pravastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + pravastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call